Magnasense
0.125
SEK
+0.64 %
MAGNA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+0.64%
-10.71%
-41.59%
-60.88%
-80.83%
-89.32%
-84.88%
-99.66%
-
-98.7%
www.aegirbio.com
Magnasense operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.
Revenue
90K
EBIT %
-62,400 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
MAGNA
Daily low / high price
0.123 / 0.136
SEK
Market cap
7.79M SEK
Turnover
16.46K SEK
Volume
129K
Financial calendar
Annual report
2025-03-28
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| CBNY-CityBank N.A | 16.7 % | 16.7 % |
| Försäkringsbolaget Avanza Pension | 3.7 % | 3.7 % |
| Rami Nader | 2.0 % | 2.0 % |
| CBNY-National Financial Services LLC | 1.6 % | 1.6 % |
| Carl-Henrik Lunneryd | 1.4 % | 1.4 % |
| Nordnet Pensionsförsäkring | 1.3 % | 1.3 % |
| Rajesh Korada | 1.1 % | 1.1 % |
| Hälsö Mekaniska AB | 0.9 % | 0.9 % |
| Grey Consulting AB | 0.8 % | 0.8 % |
ShowingAll content types
Magnasense Interim Report July - September 2024
Magnasense AB carries out previously announced directed share issue of 13,090,908 shares to Atlas Special Opportunities following called upon conversions of SEK 3.00 million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools